AAPL293.08-1.22 (-0.41%) ▼|ABBV234.89+0.13 (+0.06%) ▲|ABT90.49-0.04 (-0.04%) ▼|ACN129.15+2.14 (+1.68%) ▲|ADBE196.57-0.86 (-0.44%) ▼|AMAT588.97+3.09 (+0.53%) ▲|AMD519.74-0.11 (-0.02%) ▼|AMGN351.43+4.42 (+1.27%) ▲|AMT174.46-4.92 (-2.74%) ▼|AMZN234.27+0.16 (+0.07%) ▲|AVGO382.07+1.92 (+0.51%) ▲|AXP342.56+4.78 (+1.42%) ▲|BA220.25+3.54 (+1.63%) ▲|BAC57.73-0.18 (-0.31%) ▼|BKNG181.25+12.31 (+7.29%) ▲|BLK982.60-32.73 (-3.22%) ▼|BMY55.00-0.53 (-0.95%) ▼|BNY143.56-3.73 (-2.53%) ▼|BRK-B494.81+2.00 (+0.41%) ▲|C143.59-1.38 (-0.95%) ▼|CAT994.45+10.21 (+1.04%) ▲|CL91.88+0.45 (+0.49%) ▲|CMCSA22.64-0.16 (-0.70%) ▼|COF200.48+2.67 (+1.35%) ▲|COP106.92-3.05 (-2.77%) ▼|COST961.09+3.41 (+0.36%) ▲|CRM152.76-0.66 (-0.43%) ▼|CSCO119.73-1.42 (-1.17%) ▼|CVS101.87+0.30 (+0.30%) ▲|CVX171.45-4.53 (-2.57%) ▼|DE600.75+8.81 (+1.49%) ▲|DHR188.87+9.90 (+5.53%) ▲|DIS101.12-2.41 (-2.33%) ▼|DUK126.53+1.48 (+1.18%) ▲|EMR141.44-1.70 (-1.19%) ▼|FDX316.83-0.41 (-0.13%) ▼|GD344.32-6.02 (-1.72%) ▼|GE365.88+9.41 (+2.64%) ▲|GEV1,057.65+22.67 (+2.19%) ▲|GILD125.16+0.11 (+0.09%) ▲|GM78.95+0.00 (+0.00%) ▲|GOOG345.04-1.04 (-0.30%) ▼|GOOGL345.29-0.80 (-0.23%) ▼|GS1,076.91-17.53 (-1.60%) ▼|HD342.86+18.41 (+5.67%) ▲|HON227.42+5.05 (+2.27%) ▲|IBM262.96-1.98 (-0.75%) ▼|INTC131.65-0.63 (-0.48%) ▼|INTU262.24+4.19 (+1.62%) ▲|ISRG401.83-1.35 (-0.33%) ▼|JNJ241.00+1.92 (+0.80%) ▲|JPM333.45-0.69 (-0.21%) ▼|KO80.60+0.29 (+0.36%) ▲|LIN515.73+3.47 (+0.68%) ▲|LLY1,117.26+10.18 (+0.92%) ▲|LMT491.64-12.03 (-2.39%) ▼|LOW221.45+7.91 (+3.70%) ▲|LRCX374.80+3.47 (+0.93%) ▲|MA494.41+6.34 (+1.30%) ▲|MCD273.88+2.22 (+0.82%) ▲|MDLZ61.74+0.68 (+1.11%) ▲|MDT80.13-0.50 (-0.62%) ▼|META557.67-4.53 (-0.81%) ▼|MMM165.91+4.07 (+2.51%) ▲|MO72.07+0.46 (+0.64%) ▲|MRK120.60+1.00 (+0.84%) ▲|MS219.86-6.17 (-2.73%) ▼|MSFT365.46-8.48 (-2.27%) ▼|MU1,048.51-3.26 (-0.31%) ▼|NEE87.62+1.19 (+1.38%) ▲|NFLX71.84-0.98 (-1.35%) ▼|NKE41.82-0.56 (-1.32%) ▼|NOW93.80-2.14 (-2.23%) ▼|NVDA199.00-1.00 (-0.50%) ▼|ORCL157.53-7.63 (-4.62%) ▼|PEP142.27+0.22 (+0.15%) ▲|PFE24.04-0.68 (-2.75%) ▼|PG152.04+1.18 (+0.78%) ▲|PLTR113.50-3.20 (-2.74%) ▼|PM178.78+0.09 (+0.05%) ▲|QCOM197.41-6.72 (-3.29%) ▼|RTX185.06-1.33 (-0.71%) ▼|SBUX103.53+2.48 (+2.45%) ▲|SCHW91.39-1.78 (-1.91%) ▼|SO95.78+0.85 (+0.90%) ▲|SPG222.15+5.41 (+2.50%) ▲|T22.37-0.44 (-1.93%) ▼|TMO492.20+22.85 (+4.87%) ▲|TMUS180.79-3.78 (-2.05%) ▼|TSLA375.53-6.08 (-1.59%) ▼|TXN303.11-1.25 (-0.41%) ▼|UBER73.85+4.18 (+6.00%) ▲|UNH405.80-3.45 (-0.84%) ▼|UNP259.96+1.35 (+0.52%) ▲|UPS106.14+0.31 (+0.29%) ▲|USB60.11+0.06 (+0.10%) ▲|V332.23+3.75 (+1.14%) ▲|VZ45.68-1.05 (-2.25%) ▼|WFC84.30+0.17 (+0.20%) ▲|WMT119.00-0.42 (-0.35%) ▼|XOM136.90-2.83 (-2.03%) ▼|AAPL293.08-1.22 (-0.41%) ▼|ABBV234.89+0.13 (+0.06%) ▲|ABT90.49-0.04 (-0.04%) ▼|ACN129.15+2.14 (+1.68%) ▲|ADBE196.57-0.86 (-0.44%) ▼|AMAT588.97+3.09 (+0.53%) ▲|AMD519.74-0.11 (-0.02%) ▼|AMGN351.43+4.42 (+1.27%) ▲|AMT174.46-4.92 (-2.74%) ▼|AMZN234.27+0.16 (+0.07%) ▲|AVGO382.07+1.92 (+0.51%) ▲|AXP342.56+4.78 (+1.42%) ▲|BA220.25+3.54 (+1.63%) ▲|BAC57.73-0.18 (-0.31%) ▼|BKNG181.25+12.31 (+7.29%) ▲|BLK982.60-32.73 (-3.22%) ▼|BMY55.00-0.53 (-0.95%) ▼|BNY143.56-3.73 (-2.53%) ▼|BRK-B494.81+2.00 (+0.41%) ▲|C143.59-1.38 (-0.95%) ▼|CAT994.45+10.21 (+1.04%) ▲|CL91.88+0.45 (+0.49%) ▲|CMCSA22.64-0.16 (-0.70%) ▼|COF200.48+2.67 (+1.35%) ▲|COP106.92-3.05 (-2.77%) ▼|COST961.09+3.41 (+0.36%) ▲|CRM152.76-0.66 (-0.43%) ▼|CSCO119.73-1.42 (-1.17%) ▼|CVS101.87+0.30 (+0.30%) ▲|CVX171.45-4.53 (-2.57%) ▼|DE600.75+8.81 (+1.49%) ▲|DHR188.87+9.90 (+5.53%) ▲|DIS101.12-2.41 (-2.33%) ▼|DUK126.53+1.48 (+1.18%) ▲|EMR141.44-1.70 (-1.19%) ▼|FDX316.83-0.41 (-0.13%) ▼|GD344.32-6.02 (-1.72%) ▼|GE365.88+9.41 (+2.64%) ▲|GEV1,057.65+22.67 (+2.19%) ▲|GILD125.16+0.11 (+0.09%) ▲|GM78.95+0.00 (+0.00%) ▲|GOOG345.04-1.04 (-0.30%) ▼|GOOGL345.29-0.80 (-0.23%) ▼|GS1,076.91-17.53 (-1.60%) ▼|HD342.86+18.41 (+5.67%) ▲|HON227.42+5.05 (+2.27%) ▲|IBM262.96-1.98 (-0.75%) ▼|INTC131.65-0.63 (-0.48%) ▼|INTU262.24+4.19 (+1.62%) ▲|ISRG401.83-1.35 (-0.33%) ▼|JNJ241.00+1.92 (+0.80%) ▲|JPM333.45-0.69 (-0.21%) ▼|KO80.60+0.29 (+0.36%) ▲|LIN515.73+3.47 (+0.68%) ▲|LLY1,117.26+10.18 (+0.92%) ▲|LMT491.64-12.03 (-2.39%) ▼|LOW221.45+7.91 (+3.70%) ▲|LRCX374.80+3.47 (+0.93%) ▲|MA494.41+6.34 (+1.30%) ▲|MCD273.88+2.22 (+0.82%) ▲|MDLZ61.74+0.68 (+1.11%) ▲|MDT80.13-0.50 (-0.62%) ▼|META557.67-4.53 (-0.81%) ▼|MMM165.91+4.07 (+2.51%) ▲|MO72.07+0.46 (+0.64%) ▲|MRK120.60+1.00 (+0.84%) ▲|MS219.86-6.17 (-2.73%) ▼|MSFT365.46-8.48 (-2.27%) ▼|MU1,048.51-3.26 (-0.31%) ▼|NEE87.62+1.19 (+1.38%) ▲|NFLX71.84-0.98 (-1.35%) ▼|NKE41.82-0.56 (-1.32%) ▼|NOW93.80-2.14 (-2.23%) ▼|NVDA199.00-1.00 (-0.50%) ▼|ORCL157.53-7.63 (-4.62%) ▼|PEP142.27+0.22 (+0.15%) ▲|PFE24.04-0.68 (-2.75%) ▼|PG152.04+1.18 (+0.78%) ▲|PLTR113.50-3.20 (-2.74%) ▼|PM178.78+0.09 (+0.05%) ▲|QCOM197.41-6.72 (-3.29%) ▼|RTX185.06-1.33 (-0.71%) ▼|SBUX103.53+2.48 (+2.45%) ▲|SCHW91.39-1.78 (-1.91%) ▼|SO95.78+0.85 (+0.90%) ▲|SPG222.15+5.41 (+2.50%) ▲|T22.37-0.44 (-1.93%) ▼|TMO492.20+22.85 (+4.87%) ▲|TMUS180.79-3.78 (-2.05%) ▼|TSLA375.53-6.08 (-1.59%) ▼|TXN303.11-1.25 (-0.41%) ▼|UBER73.85+4.18 (+6.00%) ▲|UNH405.80-3.45 (-0.84%) ▼|UNP259.96+1.35 (+0.52%) ▲|UPS106.14+0.31 (+0.29%) ▲|USB60.11+0.06 (+0.10%) ▲|V332.23+3.75 (+1.14%) ▲|VZ45.68-1.05 (-2.25%) ▼|WFC84.30+0.17 (+0.20%) ▲|WMT119.00-0.42 (-0.35%) ▼|XOM136.90-2.83 (-2.03%) ▼|
27.4 C
New York
Thursday, June 25, 2026

Tag: events

newssourceFORcompanyinformationcontent1marketreleases

VolitionRx Announces Pricing of $4.6 Million Public Offering

$4.6 million upfront with up to an additional $2.3 million of potential aggregate gross proceeds upon the full exercise of warrantsHENDERSON, Nev., June 7,...

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 7, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association®, held in New Orleans, Louisiana from June 5-8, 2026.

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

Bitty & Beau’s Coffee Launches New Mini Cruiser Franchise Model

Nationally recognized coffee brand introduces a lower-cost mobile franchise designed to expand inclusion, opportunity, and entrepreneurship nationwide. ...

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk...

Three million prescriptions for Wegovy® pill since launch on January 5th serves as another milestone in one of the strongest US pharmaceutical launches by...

PUDO Inc announces earnings call for FY 2026 year end results

TORONTO, June 3, 2026 /CNW/ - PUDO Inc. ("PUDO" or the "Company") (CSE: PDO) (OTCQB: PDPTF), today announced that it will report its year...

Looney Tunes™ Land Now Open at Six Flags Magic Mountain

Complete reimagining of the park's family area offers a brand-new experience that encourages exploration across four distinct areas with loveable Looney Tunes™ characters at its heartLooney...

The Adam Foundation Commits $750,000 to the FIFA Global Citizen Education Fund, Helping Drive the Initiative Past the $50 Million Mark

Announcement made at Global Citizen Live: Rio de Janeiro ahead of the FIFA World Cup FinalLONDON, June 7, 2026 /PRNewswire/ -- The Adam Foundation,...

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsEvents

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers